Clinical Trials Logo

Bodily Distress Syndrome clinical trials

View clinical trials related to Bodily Distress Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT06025617 Recruiting - Clinical trials for Bodily Distress Syndrome

DISTRESS Trial Functional Disorders - the DISTRESS Trial

DISTRESS
Start date: June 1, 2019
Phase: N/A
Study type: Interventional

A Diagnostic Clinic for Functional Somatic Disorders (FSD) has been set up at the outpatient diagnostic center at Regionshospitalet Silkeborg. The objective of the clinic is to support General Practitioners (GPs) by offering early stage diagnostic evaluation of whether a patient has an FSD or the symptoms were caused by another physical illness or mental disorder. As a novelty in this project, Internal Medicine consultants examine the patients for FSD, after having received training in diagnosing FSD by FSD experts. By performing diagnostic evaluation for physical diseases and FSD simultaneously, the investigators believe that the new clinic shall be able to accelerate the establishment of a final diagnosis for these patients who would otherwise likely undergo a protracted diagnostic course involving sequential evaluations at various specialty clinics. The DISTRESS trial is a pragmatic randomized clinical trial which aims to evaluate the Diagnostic Clinic for FSD in terms of clinical cost-effectiveness outcomes.

NCT ID: NCT06006715 Completed - Fibromyalgia Clinical Trials

Psychiatric Disorders and Functional Somatic Disorders

Start date: November 10, 2011
Phase:
Study type: Observational

The objectives of this study are: Firstly, to investigate the association between psychiatric disorders and functional somatic disorder (FSD). Secondly, to investigate whether psychiatric disorders are risk factors for newly developed (incident) FSD after a 5-year follow-up period.

NCT ID: NCT05811663 Completed - Fibromyalgia Clinical Trials

Health Care Use and Costs of Functional Somatic Disorders

Start date: November 10, 2011
Phase:
Study type: Observational

The goal of this observational case-control study is to learn about direct healthcare use and costs of functional somatic disorders. The aim of the proposed study is to investigate the use and costs of direct healthcare for individuals with functional somatic disorders. Researchers will compare direct healthcare use and costs of individuals with functional somatic disorders and compare them with that of healthy controls and individuals with other severe physical disease, respectively.

NCT ID: NCT05631860 Completed - Fibromyalgia Clinical Trials

Psychological Risk Factors for Functional Somatic Disorders

Start date: November 10, 2011
Phase:
Study type: Observational

The objective of this study is to explore the role of neuroticism, perceived stress, and adverse life events, respectively, in the development and perpetuation of functional somatic disorders.

NCT ID: NCT05611606 Completed - Fibromyalgia Clinical Trials

Welfare Benefits in Functional Somatic Disorders

Start date: November 10, 2011
Phase:
Study type: Observational

The objective of this observational study is to estimate the number of weeks of welfare benefits, i.e. sickness benefit, unemployment benefit and social assistance, for individuals with functional somatic disorders and compare them to 1. healthy individuals, and 2. individuals with severe physical disease.

NCT ID: NCT04935307 Enrolling by invitation - Clinical trials for Bodily Distress Syndrome

Central Processing of Odour Stimuli in Patients With Functional Somatic Disorder or MCS Compared to Healthy Controls

Start date: March 23, 2021
Phase: N/A
Study type: Interventional

Background: Functional somatic disorders (FSD) are frequent in all medical settings and characterized by persistent physical symptoms that cannot be explained by other somatic or psychiatric conditions. In recent decades, a number of different types of functional somatic disorders have been defined, but so far there is no clear explanation for the pathophysiology. The high prevalence of olfactory problems in some patients with FSD suggests that olfactory symptoms are a potential diagnostic biomarker, especially in patients with multiple chemical sensitivity (MCS). The olfactory system is a unique sense with direct pathways to the limbic system, which is associated with emotion and mood. The focus on the olfactory system has revealed a significant association of this sense with numerous diseases. Hypotheses: - Patients with MCS and FSD have normal olfactory tests (normosmic subjects according to TDI score using "sniffing test") but differ in habituation test compared to healthy controls. - MCS and FSD patients have different odour perception processing in the brain as a "fingerprint" of functional somatic disorder compared to healthy controls. Research plan: The aim of this parts of the study is to identify specific MRI and paraclinical measures for MCS and BDS. In the first phase, 5 patients with MCS and 5 healthy controls will have a full clinical test of the olfactory system at the Flavour Institute, AU. In addition, they will be scanned (for "fingerprinting") where the investigators expect to find changes in olfactory connectivity similar to those seen in depression. This phase of the study will lead to a conclusion on the exact MR parameters to be used in the main study. In the second phase of the study, 10 patients with MCS, 10 with FSD, and 10 healthy controls will be evaluated using a test battery of questionnaires and paraclinical tests. Perspectives: Previous imaging studies have focused on pain stimulation paradigms, rest-state fMRI, and DTI, but the olfactory system may be the "missing link" in identifiying a quantitative candidate in terms of whole-brain computational modeling and could potentially be used as a "fingerprint" in diagnosis and treatment monitoring.

NCT ID: NCT04287218 Recruiting - Colorectal Cancer Clinical Trials

Reducing Fear of Cancer Recurrence in Danish Colorectal Cancer Survivors

Start date: May 10, 2023
Phase: N/A
Study type: Interventional

Cognitive therapy has been shown to reduce fear of cancer recurrence (FCR), mainly in breast cancer survivors. The accessibility of cognitive behavioural interventions could be further improved by Internet delivery, but self-guided interventions have shown limited efficacy. The aim of this study is to test the efficacy of a therapist guided internet-delivered intervention (TG-iConquerFear) vs. augmented treatment as usual (aTAU) in Danish colorectal cancer survivors.